# Study of Secutrelvir in Participants With COVID-19

> **NCT07746544** · PHASE3 · RECRUITING · sponsor: **Shionogi** · enrollment: 1200 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Secutrelvir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07746544
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-05
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746544, "Study of Secutrelvir in Participants With COVID-19". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*